Q1 2026 Performance Check for AI Catalyst Scanner

I'm sharing the Q1 2026 performance data for the BSI AI Catalyst Scanner, covering all weekly scans from January Week 1 through March Week 4 — 12 weekly scans and 115 total top-10 picks tracked.

Before going into the numbers, one framing point that I want to be explicit about: this performance data does not — and is not intended to — prove that the BSI AI Catalyst Scanner is a reliable tool to be used on its own for investment decision-making. The scanner's main purpose is to help readers identify potential near-term investment opportunities surrounding known and estimated catalysts roughly 45 days ahead of each weekly scan. It is one input into a broader research process, not a substitute for it.

As the data clearly shows, very few gains are maintained long term, and despite some strong win rates inside the 45-day window, the min/max range during that same period is enormous. I've also included market-cap-at-pick data for every ticker this quarter — a new addition to the dataset, added per a subscriber's request.

Q1 2026 Highlights

Out of 115 picks during the three-month period:

• 77 tickers (67%) posted gains of over 15% within 45 days of being posted.
• 31 tickers (27%) posted gains of over 30% within the same 45-day window.
• Only 46 tickers (40%) are currently in positive territory at the time of this article.
• Only 36 tickers (31%) are still up more than 10% today.

The gap between those four numbers is the whole story.

A 67% hit rate at the +15% threshold within 45 days is a meaningful signal that the scanner is consistently surfacing names with short-term upside around catalyst events. But the drop from 67% peak to 40% currently green tells you very directly that most of these gains are not held long term. Catalyst-driven biotech names spike and fade — that is the market structure they trade in, not a bug in the scanner.

The same dataset also shows huge intraperiod swings. It is entirely normal for a single name to print +50% peak and -30% trough inside the very same 45-day window. Without a plan for what to do when either of those things happens, the scanner alone is of limited use.

How to Actually Use This Data

As I mentioned in my previous post on performance data, the conclusions reinforce what I keep coming back to, and they are worth repeating:

1. Monitor price action closely with any investment made around a catalyst. Catalyst windows compress weeks of price discovery into days, sometimes hours.
2. Tight stop losses are highly recommended. The 45-day average drawdown across this dataset is significantly negative. Without a defined downside cap, peak gains evaporate quickly.
3. A clear exit strategy is absolutely necessary — decided in advance, before entry. The data above shows that holding through the peak and into the fade is the dominant failure mode.
4. Thorough due diligence is always necessary with any investment. The scanner identifies the opportunity set; it does not assess management quality, balance-sheet health, trial design, or competitive positioning. That part is on you.

A Note on Data Exclusion

One ticker has been removed from this quarter's dataset: Helus Pharma (HELP, ex-Cybin). The source price file for HELP contained mixed-currency data — USD on some days and CAD on others — which made the performance metrics unreliable enough that I would rather exclude it than publish a misleading data point. For the record, Helus did have a nice (if short-lived) run surrounding the U.S. government decision on psychedelics during the quarter. The exclusion is a data-integrity call, not a commentary on the company itself.

Below table is best viewed on a tablet or on a desktop.